Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk239512. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk239512 SCHEMBL29360933 | 1.00 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL5159251 | 0.98 | HRH3 (1.00) | HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL5427461 | 0.97 | HRH3 (0.98) | HRH3HRH1 | |
| SCHEMBL3096866 | 0.97 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL3082255 | 0.95 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL13678357 | 0.89 | HRH3 (0.80) | HRH3HRH1 | |
| SCHEMBL3100808 | 0.87 | HRH3 (0.79) | HRH3HRH1 | |
| SCHEMBL3094981 | 0.87 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL10248179 | 0.86 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL3086195 | 0.86 | HRH3 (1.00) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | claimed |
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | claimed |
| EP-2804853-A1 | THERAPEUTIC USES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-11-26 | — | — | EP | claimed |
| WO-2013107336-A1 | THERAPEUTIC USES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-07-25 | — | — | WO | claimed |
| EP-2424528-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2011051423-A1 | TREATMENT OR PROPHYLAXIS OF DEMENTIA, NEURODEGENERATIVE DISORDERS, SCHIZOPHRENIA, ADHD, SOMNOLENCE OR EPILEPSY | GLAXO GROUP LIMITED (GB) | 2011-05-05 | — | — | WO | claimed |
| US-20110014283-A1 | NOVEL DOSAGE FORM | GLAXO GROUP LIMITED (GB) | 2011-01-20 | — | — | US | claimed |
| WO-2010129242-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | claimed |
| US-7704994-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-27 | — | — | US | claimed |
| EP-2131818-A2 | NOVEL DOSAGE FORM | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| EP-1572215-B1 | BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | claimed |
| WO-2008104590-A2 | NOVEL DOSAGE FORM | GLAXO GROUP LIMITED (GB) | 2008-09-04 | — | — | WO | claimed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | claimed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| EP-1572215-A1 | BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | claimed |
| WO-2004056369-A1 | BENZO ‘ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885 |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | HRH3 211/4885HRH1 286/4885 |
| US-20150080380-A1 | Therapeutic Uses | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 6/4885 |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885HRH1 947/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | HRH3 24/4885HRH1 76/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | HRH3 243/4885HRH1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.